Iowa State Finds New Leukemia Treatment Target

Scientists at Iowa State University just identified a missing ingredient that could help leukemia cells finish what they're supposed to do: mature into healthy blood cells and complete their natural life cycle.

In aggressive leukemia, cells in our bone marrow get stuck. They never grow up into functioning blood cells, instead remaining frozen at an immature stage and crowding out the healthy cells our bodies desperately need.

Associate professor Raquel Espin Palazon and her team discovered that a protein called progranulin, combined with a cellular pathway called JAK2/STAT3, can unlock these frozen cells. When both ingredients are present, the stuck leukemia cells finally mature into white blood cells that can live out their naturally short lives and die off as they should.

The research team started by studying zebrafish, which have two types of progranulin instead of humans' single version. This made it easier to isolate what the protein does specifically in blood cells without affecting the entire body.

They found that zebrafish lacking blood cell progranulin couldn't produce mature white blood cells like macrophages and neutrophils. The cells simply stayed stuck as immature progenitors.

When researchers tried adding progranulin to human leukemia cells, nothing happened at first. But they kept digging and found the second essential ingredient: the JAK2/STAT3 pathway, which carries chemical signals from outside cells to the DNA inside.

Leukemia cells with active JAK2/STAT3 transformed when given progranulin. The long-blocked cells finally differentiated into mature white blood cells that could complete their lifecycle and die naturally instead of multiplying endlessly.

Why This Inspires

This discovery shows why patience in science pays off. When the first attempt to mature leukemia cells with progranulin failed, the team could have abandoned the idea. Instead, they went back to their zebrafish models and looked deeper until they found what was missing.

The research also revealed something unexpected: there are two types of embryonic macrophages, only one of which needs both progranulin and JAK2/STAT3 to form. The type requiring both ingredients turns out to be better at healing injuries and regenerating tissue, opening new possibilities for creating therapeutic white blood cells in laboratories.

Espin Palazon acknowledges it could take a decade or more for these findings to reach patients. But understanding how cells work, what they need to function properly, and what's missing when they malfunction is the essential first step toward developing treatments for devastating diseases.

For now, pharmaceutical companies have a new target to explore, and researchers have a clearer map of what goes wrong in aggressive leukemia and how it might be fixed.